2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.07E.02 Physician Prescribing Preferences for Adjuvant Osimertinib in Early-Stage EGFR-Mutated Non-Small Cell Lung Cancer

EP.07E.02 Physician Prescribing Preferences for Adjuvant Osimertinib in Early-Stage EGFR-Mutated Non-Small Cell Lung Cancer

Back to course

Pdf Summary

The study explores U.S. physicians' preferences in prescribing adjuvant osimertinib for early-stage EGFR-mutated non-small cell lung cancer (NSCLC). It highlights that physicians' decisions are greatly influenced by published survival outcomes associated with osimertinib and patients' willingness to commit to the treatment regimen. This underscores the necessity for clear communication and education for patients about the treatment's benefits and risks.<br /><br />The research involved a two-phase study comprising qualitative interviews and a quantitative survey among board-certified U.S. oncologists and surgeons involved in treating NSCLC. Interviews with 12 doctors identified key factors influencing prescribing decisions, which informed the development of an internet-based survey completed by 100 medical/hematological oncologists and 54 surgeons. <br /><br />Results show that medical/hematological oncologists are primary decision-makers in treatment selection, while surgeons help identify eligible patients and refer them to oncologists. Physicians preferred osimertinib over no treatment primarily due to its positive survival outcomes. However, costs to patients and healthcare systems were noted as barriers.<br /><br />Patient hesitancy toward osimertinib and the cancer's stage significantly influenced prescribing preferences. Conversely, previous chemotherapy treatment showed minimal impact. The study suggests that addressing perceived barriers and improving understanding of osimertinib benefits could enhance its prescription, ensuring eligible patients receive optimal treatment.<br /><br />In conclusion, effective communication and addressing treatment barriers are crucial for broadening the adoption of osimertinib in eligible patients, highlighting the need to incorporate findings into practice to improve outcomes for NSCLC patients.

Asset Subtitle

Yi Liang

Meta Tag

Speaker Yi Liang

Topic Early-Stage Non-small Cell Lung Cancer

Keywords

osimertinib

EGFR-mutated NSCLC

physician preferences

survival outcomes

patient education

oncologists

treatment barriers

prescribing decisions

adjuvant therapy

patient hesitancy